| Company Name: |
Shanghai Hongye Biotechnology Co. Ltd
|
| Tel: |
400-9205774 |
| Email: |
sales@glpbio.cn |
| Products Intro: |
Product Name:13,14-dihydro-15-keto-tetranor Prostaglandin E2
CAS:20675-85-8
Purity:>98% Package:1mg;10mg;50mg;100mg;
|
| Company Name: |
Shanghai Yifei Biotechnology Co. , Ltd.
|
| Tel: |
021-65675885 18964387627 |
| Email: |
customer_service@efebio.com |
| Products Intro: |
Product Name:13,14-dihydro-15-keto-tetranor Prostaglandin E2 Exclusive
CAS:20675-85-8
Purity:95% Package:10μg;25μg;50μg
|
| Company Name: |
Cayman Chemical Company
|
| Tel: |
(800) 364-9897 |
| Email: |
cayman@caymanchem.com |
| Products Intro: |
Product Name:13,14-dihydro-15-keto-tetranor Prostaglandin E2
CAS:20675-85-8
Package:>=95% Remarks:13101
|
|
| | 13,14-dihydro-15-keto-tetranor Prostaglandin E2 Basic information |
| | 13,14-dihydro-15-keto-tetranor Prostaglandin E2 Chemical Properties |
| Boiling point | 497.7±30.0 °C(Predicted) | | density | 1.127±0.06 g/cm3(Predicted) | | solubility | DMF: 50 mg/ml; DMSO: 50 mg/ml; Ethanol: 50 mg/ml; PBS (pH 7.2): 1 mg/ml | | pka | 4.61±0.10(Predicted) |
| | 13,14-dihydro-15-keto-tetranor Prostaglandin E2 Usage And Synthesis |
| Description | A common metabolic pathway for several prostaglandins (PG), including PGE2, involves the reduction of the double bond between C-13 and C-14 and oxidation of the hydroxyl group at C-15, producing 13,14-dihydro-15-keto PGs. The removal of four carbons at the α-terminus and oxidation of the terminal ω-carbon produces the abundant urinary metabolites, including tetranor PGEM.1 13,14-dihydro-15-keto-tetranor PGE2 is a potential metabolite of PGE2. It would be produced from the known metabolite 13,14-dihydro-15-keto PGE2 , which is known to have a short plasma half-life.2,3,4 | | References | 1. Hamberg, M. Inhibition of prostaglandin synthesis in man Biochem. Biophys. Res. Commun. 49(3),720-726(1972).
2. Bothwell, W., Verburg, M., Wynalda, M., et al. A radioimmunoassay for the unstable pulmonary metabolites of prostaglandin E1 and E2: An indirect index of their in vivo disposition and pharmacokinetics J. Pharmacol. Exp. Ther. 220(2),229-235(1982).
3. Fitzpatrick, F.A., Aguirre, R., Pike, J.E., et al. The stability of 13,14-dihydro-15 keto-PGE2 Prostaglandins 19(6),917-931(1980).
4. Granstr?m, E., Hamberg, M., Hansson, G., et al. Chemical instability of 15-keto-13,14-dihydro-PGE2: The reason for low assay reliability Prostaglandins 19(6),933-945(1980). |
| | 13,14-dihydro-15-keto-tetranor Prostaglandin E2 Preparation Products And Raw materials |
|